Page last checked 2026-08-13

Pineal tetrapeptide (research compound) · safety

Epitalon side effects

No controlled human trial has published a side-effect rate or safety profile for Epitalon. Here is what is actually known instead, and what that gap does and does not tell you.

Epitalon is a peptide four amino acids long, made in Leningrad in the 1980s. It copies the amino-acid makeup of an extract of cow pineal gland. It is sold for longevity — longer telomeres, better sleep, slower aging.

The lifespan results people quote were produced by the gland extract, not by this peptide. One monkey experiment ran both side by side and used five hundred times more of the extract. Two human studies of the peptide itself exist. They measured eyesight and a urine marker, and both came out of the institute that made it.

No completed controlled human trial has shown which dose works for Epitalon. There is no study-backed human dosing program to publish. Animal quantities are not converted into a human recommendation.

no human dose shown to work

Further down: when to get medical help · questions

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-13

At a glance

Common reactions listed

None published

Serious reactions listed

None published

Boxed warning

No label exists

Strongest source

no human dose shown to work

Nothing measured is not the same as nothing to find — the section below is about that difference.

When to seek medical care

Because no controlled human safety profile has been published for this compound, there is no evidence-based list of warning signs specific to it. That removes the early warning, not the risk. Any new, severe or lasting symptom belongs with a clinician. Tell them exactly what was taken.

EmergencySome symptoms should not wait for an appointment. Call emergency services (911 in the US) if they are severe, getting worse fast, or involve trouble breathing, chest pain, fainting or confusion.

3Read deeperTiming, evidence limits, and product context

Why there is no Epitalon side-effect profile here

There is no side-effect table on this page because there is no controlled human safety profile to build one from — and an empty table is more honest than a plausible one.

A published side-effect profile is not a summary of what people have noticed. It is the output of a specific process: a controlled trial enrolls a defined group and records every event, whether or not it looks related. It compares those rates against a control group, then publishes the result against a plan registered before the first dose. Where that process has not produced a profile, the output does not exist. Nothing stands in for it — not seller literature, not clinic protocols, not forum threads.

So the absence says something about the evidence, not about the compound. A profile nobody has measured is not a clean profile; it is an unmeasured one. Those two get confused constantly, and the confusion always runs in the direction that flatters the compound.

It is worth being blunt about the asymmetry. Rare and serious reactions are exactly the ones that scattered, self-reported experience is worst at catching. They are uncommon by definition, they can take time to appear, and they are easy to blame on something else.

The people who get them are also the least likely to come back and post an update. What shows up first in an unstudied compound is the mild and the immediate. That is a fact about how the reports get collected, not evidence about the compound.

The missing profile takes the rest of the scaffolding with it. With no approved label there is no list of who should avoid it, no documented interactions and no monitoring plan. There is no ceiling dose, and no channel carrying reports back to a regulator. Anyone taking an unapproved compound is outside all of those at once — and silence from a system that does not exist is not reassurance.

Epitalon has human studies. They still do not describe the injected vial.

Two groups of people received the synthetic tetrapeptide in the published research. One study placed it behind the eye and the other used it under the tongue. Neither route answers what happens when the material sold in a vial is repeatedly injected under the skin.

The human routes do not transfer to an injection under the skin

The eye study and the under-the-tongue study are evidence that people encountered the molecule. They are not an injectable safety trial. Route changes absorption, exposure and the local reactions a study is able to observe.

The eye report says that no treated patient reported a side effect. That statement belongs to medicine placed behind the eye for a short study. Moving it to a subcutaneous vial would turn a narrow observation into reassurance the research never produced.

The longevity result belongs to a pineal extract, not this peptide

The long follow-up commonly attached to Epitalon used Epithalamin, an extract made from bovine pineal glands. Epitalon is a synthetic sequence of four amino acids. The related names and shared research group do not make the materials interchangeable.

The distinction matters twice on a safety page. An extract can contain more than the named sequence, and a result from the extract cannot show either benefit or how well people handle the synthetic peptide now sold under this name.

The literature has not escaped its original research lineage

The principal human reports trace back to the institutes that developed the compound. No Western group has repeated the work, and a registry search found no study filed under either common spelling.

That does not erase the published participants. It limits what can be concluded from them: there is no independent replication, no active registered program to extend the page and no modern injected study that could show how often side effects occurred.

Regulatory review has not resolved the uncertainty

A US compounding advisory committee reviewed the substance, and the agency briefing recommended against adding it to the pharmacy bulks list. We did not find a published final decision when this guide was checked.

The proposed mechanism is not a safety shortcut either. Telomerase activity is discussed as a reason for interest in aging, but it is also machinery tumors use. A mechanism with competing implications needs human follow-up; it cannot substitute for it.

What the absence does and does not mean

Four readings of an empty safety record go around. Each one turns a missing measurement into reassurance.

The claim	What the evidence shows
Nothing serious has been reported.	Nothing has been systematically collected. A report needs a system that receives it, strips out duplicates and counts it. For an unapproved compound there is no such system, so silence is what you would get either way.
The studies look clean.	The published work is overwhelmingly in animals or too small and uncontrolled to produce a safety rate. Animal findings do not carry over to people at human doses over human timescales, and uncontrolled exposure supplies no comparison group or denominator.
People have used it for years.	Informal use is not monitoring. Years of unmeasured use produce familiarity and confidence. They do not produce a denominator, a comparison group, or a rate.
People seem to handle it well.	How well people handle a compound is measured against a control group. Without that comparison, the claim is only the writer’s impression.

No human safety profile has been published for this compound. If that changes, the results should be reported with the study size, comparison group and citation—not filled in with assumptions.

Common questions

Does Epitalon have known side effects?

No controlled human study has published a side-effect rate or safety profile. That describes the missing evidence, not the compound: unmeasured does not mean safe.

Is Epitalon safe?

The published human evidence cannot answer that either way. Reliable safety estimates need systematic collection, a total number treated and a comparison group; none is available here.

What should someone do about symptoms after taking an unapproved compound?

Take the symptom to a clinician, and say exactly what was taken, how much and for how long. Clinicians assess symptoms without needing an approved label to exist, and leaving out the detail removes the one piece of context that changes what they look for.

The schedule these reactions were recorded against, the comparisons, and the sourcing rules behind every grade on this page.

How epitalon differs from the rest of its class

No published human dosing schedule was found for epitalon.

The epitalon reconstitution math, shown rather than hidden

No use-by period has been published for epitalon, so the tool reports none.

The generic calculator behind the epitalon one

Vial strength and water volume in and the exact mark out, with epitalon as context

Where epitalon stands with the regulator, and when

Approval status, proceedings and the date attached to each, with epitalon as one example

Every compound guide, epitalon and the rest

Class, approval status and strongest available source for every compound, with epitalon as one example

Why these epitalon sources were chosen

How an FDA label differs from a human trial or a claim with no human data, with epitalon as one example